We value your privacy
We use cookies to enhance your browsing experience, serve personalized ads or content, and analyze our traffic. By clicking "Accept All", you consent to our use of cookies.
We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.
The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ...
Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.
No cookies to display.
Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.
No cookies to display.
Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.
No cookies to display.
Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.
No cookies to display.
Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.
No cookies to display.
A vaccination against the respiratory syncytial virus (RSV), which claims the lives of thousands of Americans each year, has been licenced by the US Food and Drug Administration.
Before being made available to the general public, the vaccine still need approval from the US Centres for Disease Control and Prevention.
According to authorities, the vaccine, called Arexvy by the maker GSK, is a significant advancement that will save many lives.
In a few months, senior citizens might have access to it, according to officials.
“Today’s approval of the first RSV vaccine is an important public health achievement to prevent a disease which can be life-threatening,” said Dr. Peter Marks, director of the Food and Drug Administration’s (FDA) Centre for Biologics Evaluation and Research.
RSV is a respiratory disease that normally affects adults and causes cold-like symptoms, but it can be deadly for small children, the elderly, and people with underlying medical issues.
According to the CDC, it typically kills 100–300 children under the age of five in the US every year.
Additionally, it results in 6,000 to 10,000 deaths of adults over 65 each year and 60,000 to 120,000 hospital admissions.
In extreme circumstances, it can lead to bronchiolitis, which includes an accumulation of lung inflammation and breathing difficulties.
The medication has been in development for more than 60 years and is the first to be approved globally to prevent RSV.
A study conducted by the UK-based company GSK and released in February revealed a vaccination efficacy of 82.6%.
Most “mild or moderate” side effects subsided within two days. The most typical symptoms are weariness or soreness at the injection site.
RSV can advance from a blocked or runny nose to a dry cough, fever, and occasionally breathing issues.
Most kids will only experience moderate symptoms, which can be handled at home with infant paracetamol or ibuprofen.
If your child is not eating regularly, is breathing quickly, or has a high temperature that won’t go down, call a doctor or get medical help.
If your child is struggling to breathe and is showing signs of exhaustion, such as paleness and perspiration, you should call emergency services right away.
© 2023 Global Updates